AstraZeneca (AZNCF) Stock Chart & Stock Price History $157.09 -0.71 (-0.45%) As of 03:11 PM Eastern Add Compare Share Share Chart Stock AnalysisChartDividendFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock AstraZeneca Stock Price Performance The AstraZeneca (AZNCF) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 7.32%, with a year-to-date return of 20.84%. In the past month, the stock has increased 10.70%, reflecting recent market activity. As of the latest close, AstraZeneca traded at $157.80 with a market cap of and volume of 585 shares. Receive AZNCF Stock News and Ratings via EmailSign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+1.02%1 Month Performance+10.70%3 Month Performance+11.32%Year-To-Date Performance+20.84%1 Year Performance-7.32% AZNCF Stock Chart for Friday, August, 22, 2025 AZNCF Chart by TradingView AstraZeneca Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025$157.80$157.09-0.45%$161.74$157.097,386 shs$0.0008/21/2025$157.80$157.80$157.80$157.80585 shs$0.0008/20/2025$160.46$157.80-1.66%$157.80$157.80585 shs$0.0008/19/2025$160.46$160.46$160.46$156.701,179 shs$0.0008/18/2025$155.50$160.46+3.19%$160.46$156.701,179 shs$0.0008/15/2025$155.75$155.50-0.16%$155.50$155.5019,429 shs$0.0008/14/2025$154.30$155.75+0.94%$155.75$155.7510,478 shs$0.0008/13/2025$150.78$154.30+2.33%$156.78$152.251,592 shs$0.0008/12/2025$146.12$150.78+3.19%$150.78$146.75798 shs$0.0008/11/2025$141.77$146.12+3.07%$147.11$146.121,474 shs$0.00 Get the Latest News and Ratings for AZNCF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. 08/08/2025$147.24$141.77-3.71%$141.77$141.771,387 shs$0.0008/07/2025$148.68$147.24-0.97%$149.67$143.221,125 shs$0.0008/06/2025$150.29$148.68-1.07%$149.52$148.681,044 shs$0.0008/05/2025$150.32$150.29-0.02%$150.68$145.0113,543 shs$0.0008/04/2025$147.50$150.32+1.91%$150.32$141.80945 shs$0.0008/01/2025$147.39$147.50+0.07%$151.37$147.5034,722 shs$0.0007/31/2025$155.67$147.39-5.32%$150.74$147.39624 shs$0.0007/30/2025$150.48$155.67+3.45%$155.67$151.001,130 shs$0.0007/29/2025$144.10$150.48+4.43%$150.48$149.05512 shs$0.0007/28/2025$146.92$144.10-1.92%$144.10$144.101,187 shs$0.0007/25/2025$146.92$146.92$150.00$146.92936 shs$0.0007/24/2025$147.30$146.92-0.26%$150.00$146.92936 shs$0.0007/23/2025$141.90$147.30+3.81%$147.30$142.001,820 shs$0.0007/22/2025$139.70$141.90+1.57%$141.90$138.00610 shs$0.0007/21/2025$142.02$139.70-1.63%$139.92$139.70986 shs$0.00 Related Companies 180 Life Sciences Stock Chart 4D pharma Stock Chart 4Front Ventures Stock Chart Abattis Bioceuticals Stock Chart Abcam Stock Chart Acusphere Stock Chart Adhera Therapeutics Stock Chart Aeolus Pharmaceuticals Stock Chart Aesther Healthcare Acquisition Stock Chart Agentix Stock Chart Receive AZNCF Stock News and Ratings via EmailSign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:AZNCF) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access